Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms alleviate 1
- Sponsors Novo Nordisk
- 02 Jan 2018 Planned End Date changed from 31 Dec 2018 to 30 Nov 2018.
- 02 Jan 2018 Planned primary completion date changed from 31 Dec 2018 to 30 Nov 2018.
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.